Меню
Идёт набор NCT06755684

Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer

Фаза II С лечением EGFR Non-Small Cell Lung Cancer Locally Advanced Non-Small Cell Lung Cancer Pemetrexed

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: Befotertinib combined Bevacizumab, Befotertinib combined platinum-based double chemotherapy.
Кому может быть актуально
Состояния в реестре: EGFR, Non-Small Cell Lung Cancer, Locally Advanced Non-Small Cell Lung Cancer, Pemetrexed. Базовые параметры: от 18 лет · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
Китай
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →

Не всё понятно в терминах? Прочитайте наш гид для пациентов →

Официальное название

Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer: a Single-center, Randomized Controlled Trial

Обзор

This study targeted patients with resectable stage II-IIIA non-small cell lung cancer with EGFR mutation

Вмешательства

  • Препарат Befotertinib combined Bevacizumab
    Befotertinib combined Bevacizumab
  • Препарат Befotertinib combined platinum-based double chemotherapy
    Befotertinib combined platinum-based double chemotherapy

Первичные конечные точки

  • Major pathologic response (MPR) [Срок оценки: up to 4 months]
Вторичные конечные точки (8)
  • Objective response rate (ORR) [Срок оценки: Up to 4 months]
  • Progression-free survival (PFS) [Срок оценки: up to 60 months]
  • Event-free survival (EFS) [Срок оценки: Up to 60 months]
  • Disease-free survival (DFS) [Срок оценки: up to 60 months]
  • Overall survival (OS) [Срок оценки: up to 60 months]
  • R0 rate [Срок оценки: up to 4 months]
  • adverse event (AE) rate [Срок оценки: up to 4 months]
  • Complete Pathological response (CPR) [Срок оценки: Up to 4 months]

Критерии участия

Критерии включения

  • NSCLC patient with EGFR sensitive mutation as confirmed by needle biopsy;
  • At stage II-IIIA (TNM Staging, Version 8) as identified by chest CT, PET-CT or/and EBUS;
  • No systemic metastasis (confirmed by head MRI, whole body bone scan, PET-CT, liver and adrenal CT, etc.);
  • With the feasibility to receive radical surgery ;
  • Good lung function that could tolerate surgical treatment;
  • Aged 18-75 years;
  • At least one measurable tumor foci (the longest diameter measured by CT shall be > 10 mm);
  • Other major organs shall function well (liver, kidney, blood system, etc.):
  • ECOG PS score shall be 0-1;
  • The child-bearing female must undergo pregnancy test within 7 days before starting the treatment and the result shall be negative. Reliable contraceptive measures, such as intrauterine device, contraceptive pill and condom, shall be adopted during the trial and within 30 days after completion of the trial. The child-bearing male shall use condom for contraception during the trial and within 30 days after completion of the trial;
  • The patient shall sign the Informed Consent Form.

Критерии исключения

  • The patient has undergone any systemic anti-cancer treatment for NSCLC, including surgical treatment, local radiotherapy, cytotoxic drug treatment, targeted drug treatment and experimental treatment, etc.;
  • The patient suffers from any unstable systemic disease (including active infection, uncontrolled hypertension, unstable angina pectoris, angina pectoris that starts to attack within the last 3 months, congestive heart failure \[≥ Grade II specified by New York Heart Association (NYHA)\], cardiac infarction (6 months before enrollment), severe arrhythmia and liver, kidney or metabolic diseases that requires drug treatment;
  • The patient is a carrier of HIV;
  • The patient has had or is currently suffering from interstitial lung disease;
  • The patient had undergone other major systemic operations or suffered from severe trauma within 3 months before the trial;
  • The patient is allergic to befotertinib or its any excipients;
  • The patient is allergic to bevacizumab or its any excipients;
  • The patient is allergic to platinum-based double chemotherapy or its any excipients;
  • The female patient is in pregnancy or lactation period;
  • There are any conditions under which the investigator considers the patient is not suitable to be enrolled.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение
Рандомизированное
Модель
Параллельные группы
Маскирование
Открытое
Основная цель
Лечение

Центры проведения

Китай · 1 центр
  • Shanghai Pulmonary Hospital — Шанхай

Идентификаторы

NCT: NCT06755684 · LungMate-021

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗